Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts)

Leonardo M. Fabbri, Gary T. Ferguson, Shahid Siddiqui, Chad Orevillo, Patrick Darken, Colin Reisner, Fernando J. Martinez
  • European Respiratory Journal, September 2016, European Respiratory Society (ERS)
  • DOI: 10.1183/13993003.congress-2016.pa992

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1183/13993003.congress-2016.pa992

In partnership with: